RecruitingPhase 4NCT06765265
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Sponsor
King Edward Medical University
Enrollment
152 participants
Start Date
Jan 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Atorvastatin 40 mg and a drug called Rosuvastatin 20 mg/day for people with acute coronary syndromes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRosuvastatin 20 mg/day
Rosuvastatin 20 mg / Day for 24 weeks
DRUGAtorvastatin 40 mg
Atorvastatin 40mg / Day for 24 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06765265
Related Trials
Oregano and Basil Leaves and Coronary Artery Disease
NCT071231811 location
Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease
NCT075882951 location
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
NCT075828351 location
Point-of-Care Troponin Testing in the Emergency Department
NCT068458261 location
A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices
NCT068900131 location